[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National Jewish Health\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":204},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,38,63,94,116,139,160,183],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100288468","deployment-related-lung-disease-research-database-and-biorepository-100288468",false,"NCT03035097","Deployment-Related Lung Disease Research Database and Biorepository","Inclusion Criteria:\n\n* Served in the southwest Asia wars\n\nExclusion Criteria:\n\n* Did not served in the southwest Asia wars","ALL","18 Years",{"count":18,"type":19},500,"ESTIMATED","1 Day","OBSERVATIONAL","The purpose of this research study is to establish a research database and biorepository for patients at National Jewish Health (NJH) who served in Operation Iraqi Freedom (OIF) or Operation Enduring Freedom (OEF). This study will also include civilian contractors who worked as part of these military operations in Iraq or Afghanistan. The biorepository would store blood samples obtained from these patients during a clinic visit. The research database would store prospectively and retrospectively collected clinical and exposure data that would enable us to comprehensively characterize each case.",[24],"Bronchiolitis","RECRUITING","2026-04-10",{"date":28,"type":29},"2026-04-15","ACTUAL",{"date":31,"type":4},"2013-02",{"date":33,"type":19},"2030-12",{"name":35,"class":36},"National Jewish Health","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":15,"minAge":45,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":37},"100549553","phase-4-enhancing-hypnotic-medication-discontinuation-in-primary-care-100549553","NCT06435520","Enhancing Hypnotic Medication Discontinuation in Primary Care","Enhancing Hypnotic Medication Discontinuation in Primary Care Through Supervised Medication Tapering and Digital Cognitive Behavioral Insomnia Therapy","Inclusion Criteria:\n\n* a history of extended (\\> 6 consecutive months) and frequent (\\>5 nights\u002Fweek on average) use of benzodiazepine (BZD) or non-BZD hypnotic medications;\n* a desire to decrease\u002Feliminate hypnotic use;\n* a history of insomnia that meets DSM-560 criteria for insomnia disorder; and\n* willingness to provide written informed consent to participate.\n\nExclusion Criteria:\n\n* a lifetime diagnosis of any psychotic disorder, suicide attempts, or bipolar disorder;\n* presence of an unstable, untreated, or terminal major medical or psychiatric disorder;\n* alcohol or drug abuse within the past year;\n* current use of a BZD for another disorder in addition to insomnia (e.g., seizure disorder, restless leg syndrome, anxiety disorder);\n* pregnancy;\n* significant cognitive impairment as suggested by a score of ≤ 24 on the Folstein Mini-Mental State Examination (MMSE);\n* current use of medications known to cause insomnia (e.g., high dose corticosteroids);\n* untreated comorbid sleep disorders;\n* use of a sedating antidepressant or antipsychotic medication solely for sleep; and\n* consuming \\>2 alcoholic beverages\u002Fday ≥5 times\u002Fweek or any use of marijuana ≥5 times\u002Fweek.","21 Years",{"count":47,"type":19},430,"INTERVENTIONAL",[50],"PHASE4","Many individuals with insomnia seek treatment in primary care settings, where they often receive prescription hypnotic medications as their first and sometimes only treatment. However, extended use of these medications can lead to reliance and increased health risks, such as falls and cognitive impairments. While evidence-based approaches like physician-supervised medication tapering exist, they're not widely available in primary care.\n\nMost primary care providers are willing to explore non-drug treatments like cognitive behavioral therapy for insomnia (CBTI), but accessing such treatments can be challenging outside of specialized sleep centers. This gap between research and practice underscores the need for cost-effective interventions to manage insomnia and help patients reduce their reliance on hypnotics in primary care.\n\nIn response to this need, the project aims to conduct a large randomized trial comparing a combined digital CBT (dCBTI) and medication tapering intervention with medication tapering alone. We'll recruit 430 patients reliant on hypnotics from 8-10 primary care clinics affiliated with the University of Colorado Medical School. The main goal is to assess the effectiveness of dCBTI+SMT compared to SMT alone in reducing hypnotic use and improving insomnia symptoms.\n\nAdditionally, we'll evaluate factors affecting the adoption and implementation of these interventions at the patient, provider, and system levels. This information will inform future implementation strategies to disseminate effective treatments in primary care.\n\nFurthermore, we'll gather data to identify which patients benefit most from dCBTI+SMT. Overall, this study will provide valuable insights into the feasibility, clinical utility, and acceptability of these interventions in managing insomnia and reducing reliance on hypnotic medications in primary care. Ultimately, this project represents a crucial first step toward making accessible and cost-effective strategies available to improve the quality of life for millions of chronic users of sleep aids.",[53,54],"Insomnia","Hypnotic Dependence","2026-01-22",{"date":57,"type":29},"2026-01-23",{"date":59,"type":29},"2025-01-01",{"date":61,"type":19},"2029-06-30",{"name":35,"class":36},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":15,"minAge":70,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":48,"phases":73,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":37},"100610054","moboxy-moblo2-to-maintain-oxygenation-100610054","NCT07222592","MOBoxy: MoblO2 to Maintain Oxygenation","MOBoxy","Inclusion Criteria:\n\n1. Previously-diagnosed COPD or chronic ILD\n2. Prescribed O2 for use with exertion at least 1 month prior to enrollment\n3. Age 25 years old or greater\n4. Self-reported stable symptoms and stable oxygen needs for at least 2 weeks\n5. Patient consent to using compressed gas tanks to deliver O2 during the 2-week study period.\n\nExclusion Criteria:\n\n1. Active angina\n2. Hemoglobin less than 10mg\u002FdL\n3. Musculoskeletal disease that precludes physical activity\n4. Ongoing participation or plans for participation in pulmonary rehabilitation during the study\n5. Need for O2 at rest\n6. Patient needing more than 10 L\u002Fmin continuous flow with exertion on O2 screen. Patient prescribed 10L\u002Fmin continuous flow (or more) by their prescribing physician","25 Years",{"count":72,"type":19},48,[74],"NA","Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL).\n\nHowever, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as \"smokers who get what they deserve, even if they never smoked a day in their lives\" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives.\n\nO2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary .\n\nThe MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis.\n\nThe user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \\> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial.\n\nGiven the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it.\n\nThe purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.",[77,78],"COPD","Interstitial Lung Disease",[77,80,81,82,83,84],"interstitial lung disease","pulmonary fibrosis","supplemental oxygen","symptoms","quality of life","NOT_YET_RECRUITING","2025-10-28",{"date":88,"type":29},"2025-10-30",{"date":90,"type":19},"2025-12",{"date":92,"type":19},"2026-08",{"name":35,"class":36},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":100,"sex":15,"minAge":16,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":48,"phases":104,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":37},"100351684","alveolar-macrophage-programming-following-endotoxin-exposure-100351684","NCT03859050","Alveolar Macrophage Programming Following Endotoxin Exposure","Inclusion Criteria:\n\n1. Written, informed consent\n2. Age 18-50\n\nExclusion Criteria:\n\n1. Current or recent illness (past 2 weeks)\n2. Presence or prior history of cardiac, pulmonary or systemic disease\n3. Bleeding disorder, use of systemic anticoagulants or antiplatelet therapy\n4. American Society of Anesthesiology (ASA) class 2 or greater\n5. Immunocompromised state (HIV, immunoglobulin deficiency, systemic immunosuppressants)\n6. Use of any inhaled substance, including tobacco, marijuana, e-cigarrettes, cocaine, methamphetamines, or toxic vapors in the past 3 months or greater than 10 pack-year smoking history\n7. Alcohol use disorder or greater than 7 drinks\u002Fweek for women or greater than 14 drinks\u002Fweek for men in the past 3 months\n8. Allergy or prior adverse reaction to lidocaine, midazolam or fentanyl\n9. Abnormal spirometry or electrocardiogram at time of screening\n10. Pregnant (based on urine pregnancy test) or breast feeding",true,"50 Years",{"count":103,"type":19},25,[74],"The histologic hallmarks of lung inflammation include accumulation of inflammatory cells in the airspaces and interstitium, injury to alveolar epithelial and endothelial cells, loss of epithelial-capillary integrity and accumulation of edema fluid in the interstitium and airspaces. Accordingly, for alveolar repair to occur inflammation must be halted, debris and inflammatory cells removed, injured tissue cells replaced, and capillary barrier function re-established. Macrophages are key players in all of these. Here the investigators hypothesize that resident alveolar macrophages and recruited macrophages serve completely different functions, acting independently (i.e. division of labor) yet cooperatively (synergism).",[107],"ARDS, Human","2025-05-02",{"date":110,"type":29},"2025-05-06",{"date":112,"type":29},"2019-03-18",{"date":114,"type":19},"2032-07",{"name":35,"class":36},{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":100,"sex":15,"minAge":122,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":48,"phases":126,"briefSummary":127,"conditions":128,"keywords":131,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":37},"100563653","phase-4-effect-of-omalizumab-in-the-skin-of-food-allergy-patients-100563653","NCT06618963","Effect of Omalizumab in the Skin of Food Allergy Patients","Inclusion Criteria:\n\n* Participant and\u002For parent\u002Flegal guardian must be able to understand and provide informed consent and\u002For assent, as applicable.\n* Male or female, 1-55 years old at screening.\n* Total IgE level within 1 year of screening and weight at screening visit that together result in an eligible omalizumab dose according to the dosing table for FA (Appendix 8).\n* Participant must meet the following clinical FA criteria: Food sensitization to peanut, hen's egg, a tree nut, sesame seed, cow's milk, wheat, or soy, within 1 year of screening AND experience dose-limiting, IgE mediated symptoms at or before 444mg of food protein cumulatively during screening OFC to peanut, hen's egg, a tree nut, sesame seed, cow's milk, wheat, or soy.\n* If female of child-bearing potential, must have a negative urine or serum pregnancy test. If participating as a healthy control, self-report of pregnancy status is acceptable.\n* For women of child-bearing potential, must agree to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraceptive methods (barrier methods or oral, injected, or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy) during the treatment period and for 60 days after the last dose of study drug.\n* Be willing to be trained on the proper use of an epinephrine autoinjector and be willing to always have epinephrine autoinjector immediately available for the duration of the study.\n\nExclusion Criteria:\n\n* Inability or unwillingness of a participant and\u002For parent\u002Flegal guardian to give written informed consent and\u002For assent or comply with the study protocol.\n* Clinically significant laboratory abnormalities at Screening.\n* Sensitivity or suspected\u002Fknown allergy to any ingredients (including excipients) of the active OFC material (other than the study food), or drugs related to omalizumab (e.g., monoclonal antibodies, polyclonal gamma globulin).\n* Poorly controlled AD at Screening, per the PI's discretion.\n* Poorly controlled or severe asthma\u002Fwheezing at Screening\n* History of severe anaphylaxis (defined as neurological compromise or requiring intubation) to a study food that is to be used for qualifying OFC in this study.\n* Treatment with oral, intramuscular (IM), or intravenous (IV) steroids of more than two days for an indication other than asthma\u002Fwheezing within 30 days of Screening.\n* Currently receiving oral, IM, or IV corticosteroids, tricyclic antidepressants, or β-blockers (oral or topical).\n* Past or current history of cancer, or currently being investigated for possible cancer.\n* Previous adverse reaction to omalizumab.\n* Past or current history of any immunotherapy to the OFC food (e.g., oral immunotherapy \\[OIT\\], sublingual immunotherapy \\[SLIT\\], or patch\u002Fepicutaneous immunotherapy \\[EPIT)\\] within 4 months of Screening.\n* Treatment with monoclonal antibody therapy, such as omalizumab (Xolair®), dupilumab (Dupixent®), benralizumab (Fasenra™), mepolizumab (Nucala®), reslizumab (Cinqair®), or other immunomodulatory therapy within four months of Screening.\n* Currently on \"build-up phase\" of inhalant allergen immunotherapy (i.e., has not reached maintenance dosing). Individuals tolerating maintenance allergen immunotherapy can be enrolled.\n* Inability to discontinue antihistamines for the minimum wash-out periods required for SPTs or OFCs\n* Current participation in another therapeutic or interventional clinical trial or participation within 90 days of Screening.\n* Use of investigational drugs within 24 weeks of Screening.\n* Pregnant or breastfeeding or intending to become pregnant during the study or within 60 days after the last dose of omalizumab.\n* Have any skin disease other than AD that might compromise the stratum corneum barrier.\n* History of serious life-threatening reaction to tape or adhesives.\n* Healthy Control Participants (non-Food Allergy participants) may not have atopic dermatitis, autoimmune, or other conditions which, in the opinion of the PI, could confound the results of the study assessments or samples.","1 Year","55 Years",{"count":125,"type":19},40,[50],"The goal of this interventional study is to evaluate whether skin barrier abnormalities occur in subjects with a food allergy, as determined by positive oral food challenge (OFC). The main question it aims to answer is whether these skin barrier abnormalities can be reversed by omalizumab.\n\nIf there is a comparison group: Researchers will compare non-food allergic participants (who do not receive omalizumab) to see if they experience skin barrier abnormalities.\n\nAll food allergic participants will receive 4 months of Omalizumab treatment as well as two Oral Food Challenges. Participants will all undergo skin barrier assessments.",[129,130],"Food Allergy","Food Allergy in Children",[129],"2025-04-29",{"date":108,"type":29},{"date":135,"type":29},"2024-10-01",{"date":137,"type":19},"2026-12",{"name":35,"class":36},{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":15,"minAge":145,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":159,"locationsCount":37},"100317876","the-role-of-laryngopharyngeal-reflux-in-ipf-100317876","NCT03418350","The Role of Laryngopharyngeal Reflux in IPF","Inclusion Criteria:\n\n* Diagnosis of IPF\n* Age 40-95\n* Able to read, speak, and understand English\n* If subjects are currently taking medication for reflux or GERD, they much be on a stable does for at least 4 weeks prior to consent.\n\nExclusion Criteria:\n\n* Patients who do not meet all inclusion criteria\n* Pregnant females","40 Years","95 Years",{"count":148,"type":19},60,"The primary objective of this study is to show that the Supraglottic Index (SGI) is an easily-collected index that accurately identifies the presence and severity of laryngopharyngeal reflux (LPF) in idiopathic pulmonary fibrosis (IPF).",[151,152],"IPF","Reflux","2024-11-12",{"date":155,"type":29},"2024-11-14",{"date":157,"type":29},"2018-08-01",{"date":137,"type":19},{"name":35,"class":36},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":100,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":48,"phases":169,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":37},"100536880","phase-1-nasal-inflammation-following-endotoxin-challenge-in-patients-with-asthma-100536880","NCT06270576","Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma","Nasal Endotoxin Challenge to Study Mucosal Inflammation in Patients With Asthma","Nasal-LPS","Inclusion Criteria:\n\n* Participants will have asthma diagnosed by a health care provider. Healthy controls are individuals without asthma.\n* Written informed consent\n\nExclusion Criteria:\n\n* Current or recent illness (in the past 4 weeks)\n* Recent asthma exacerbation (past 4 weeks)\n* History of nasal perforation or nasal surgery\n* Nasal polyposis\n* Presence or prior history of cardiac or systemic disease\n* Bleeding disorder, use of systemic anticoagulants, or antiplatelet therapy\n* Immunocompromised state (HIV, immunoglobulin deficiency, systemic immunosuppressants excluding corticosteroids)\n* Use of tobacco or marijuana in the past 2 months or greater than a 10 pack-year smoking history\n* Currently pregnant or breastfeeding",{"count":148,"type":19},[170],"PHASE1","A phase I clinical research study aimed at determining mechanisms that regulate airway mucosal inflammation in asthma endotypes using intranasal administration of endotoxin (lipopolysaccharide from E. coli) in healthy controls and subjects diagnosed with asthma.",[173,174],"Asthma; Eosinophilic","Asthma","2024-02-13",{"date":177,"type":29},"2024-02-21",{"date":179,"type":19},"2024-04",{"date":181,"type":19},"2028-06",{"name":35,"class":36},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":48,"phases":193,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":201,"leadSponsor":203,"locationsCount":37},"100281781","phase-2-reslizumab-in-the-treatment-of-eosinophilic-granulomatosis-with-polyangiitis-egpa-study-100281781","NCT02947945","Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study","Open-Label, to Evaluate the Efficacy and Safety of Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study: RITE Study","RITE","Inclusion Criteria:\n\n* Informed Consent: Able to give written informed consent prior to participation in the study, which will include the ability to comply with the requirements and restrictions listed in the consent form. Subjects must be able to read, comprehend, and write at a level sufficient to complete study related materials.\n* Gender and Age: Male or female subjects \\>18 years old\n* EGPA diagnosis: subjects who have been diagnosed with EGPA for at least 6 months based on the history or presence of: asthma plus eosinophilia (\\>1.0x109\u002FL and\u002For \\>10% of leucocytes) plus at least two of the following additional features of EGPA:\n\n  * A biopsy showing histopathological evidence of eosinophilic vasculitis, or perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation;\n  * Neuropathy, mono or poly (motor deficit or nerve conduction abnormality);\n  * Pulmonary infiltrates, non-fixed;\n  * Sino-nasal abnormality;\n  * Cardiomyopathy (established by echocardiography or MRI);\n  * Glomerulonephritis (haematuria, red cell casts, proteinuria);\n  * Alveolar haemorrhage (by bronchoalveolar lavage);\n  * Palpable purpura;\n  * ANCA positive (MPO or PR3).\n* Subjects who have received a cyclophosphamide (CYC) induction regimen may be included a minimum of 2 weeks after the last dose of daily oral CYC, or 3 weeks after the last dose of pulsed IV CYC prior to visit 1, if their total WBC is ≥4x109\u002FL prior to visit 1.\n* Subjects who have received a methotrexate, azathioprine, or mycophenolate mofetil induction regimen may be included if on a stable dose for at least 4 weeks prior to visit 1.\n* Corticosteroid therapy: Subject must be on a stable dose of oral prednisolone or prednisone of ≥5 mg\u002Fday for at least 4 weeks prior to visit 1.\n* Immunosuppressive therapy: If receiving immunosuppressive therapy (including methotrexate, azathioprine, or mycophenolate mofetil, but excluding restricted medications below) the dosage must be stable for the 4 weeks prior to visit 1 and during the study (dose reductions for safety reasons will be permitted).\n* Female subjects: To be eligible for entry into the study, females of childbearing potential (FCBP) must commit to consistent and correct use of an acceptable method of birth control beginning with consent, for the duration of the trial.\n\nExclusion Criteria:\n\n* Hypereosinophilic Syndrome\n* Wegener's Granulomatosis\n* Malignancy\n* Parasitic disease\n* Pregnant or nursing\n* If female and of child-bearing potential, must have negative pregnancy test and must adhere to acceptable method of contraception (with \\\u003C1% failure rate) during the study and for four months after the study.\n* Any other medical illness that precludes study involvement\n* Patients who are currently receiving or have previously received reslizumab or any other type of anti-interleukin therapy (i.e. mepolizumab, lebrikizumab etc.) within the last three months.\n* Taking cyclophosphamide\n* Any patients with a known hypersensitivity to reslizumab or any of its excipients",{"count":192,"type":19},10,[194],"PHASE2","Reslizumab is a type of medicine called a monoclonal antibody that is made in the research clinic; it works by blocking a specific protein in the body called interleukin-5. The study medicine, reslizumab, is not yet approved for doctors to treat patients with EGPA. It is considered an experimental drug in this study.",[174],"2017-09-12",{"date":199,"type":29},"2017-09-14",{"date":197,"type":29},{"date":202,"type":19},"2018-12",{"name":35,"class":36},""]